Potential Effects of Gut Microbiota on Host Cancers: Focus on Immunity, DNA Damage, Cellular Pathways, and Anticancer Therapy

Overview

Journal ISME J

Publisher Oxford University Press

Specialties Environmental Health
Microbiology

Date 2023 Aug 8

PMID 37553473

Authors

Jiaao Sun

Feng Chen

Guangzhen Wu

Affiliations

Soon will be listed here.

Abstract

The symbiotic bacteria that live in the human gut and the metabolites they produce have long influenced local and systemic physiological and pathological processes of the host. The gut microbiota are increasingly being recognized for its impact on a range of human diseases, including cancer, it may play a key role in the occurrence, progression, treatment, and prognosis of many types of cancer. Understanding the functional role of the gut microbiota in cancer is crucial for the development of the era of personalized medicine. Here, we review recent advances in research and summarize the important associations and clear experimental evidence for the role of the gut microbiota in a variety of human cancers, focus on the application and possible challenges associated with the gut microbiota in antitumor therapy. In conclusion, our research demonstrated the multifaceted mechanisms of gut microbiota affecting human cancer and provides directions and ideas for future clinical research.

Citing Articles

Unlocking the Microbial Symphony: The Interplay of Human Microbiota in Cancer Immunotherapy Response.

Chacon J, Faizuddin F, McKee J, Sheikh A, Vasquez Jr V, Gadad S Cancers (Basel). 2025; 17(5).

PMID: 40075661 PMC: 11899421. DOI: 10.3390/cancers17050813.

Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation.

Sun J, Song S, Liu J, Chen F, Li X, Wu G NPJ Biofilms Microbiomes. 2025; 11(1):43.

PMID: 40069181 PMC: 11897378. DOI: 10.1038/s41522-025-00678-x.

Bacteria-tumor symbiosis destructible novel nanocatalysis drug delivery systems for effective tumor therapy.

Zang J, Yin F, Liu Z, Li F, Zhang Y Nanomedicine (Lond). 2025; 20(3):305-318.

PMID: 39889806 PMC: 11792809. DOI: 10.1080/17435889.2024.2443388.

Gut microbiota, metabolites, and cytokines in relation to the risk of prostate cancer in the Asian population.

Wang Z, Chen H, Liu Y, Zou L, Zhang Z, Yin Z Front Oncol. 2025; 14:1466190.

PMID: 39882449 PMC: 11774728. DOI: 10.3389/fonc.2024.1466190.

Gut microbiota interact with breast cancer therapeutics to modulate efficacy.

Arnone A, Ansley K, Heeke A, Howard-McNatt M, Cook K EMBO Mol Med. 2025; 17(2):219-234.

PMID: 39820166 PMC: 11822015. DOI: 10.1038/s44321-024-00185-0.

References

Zhang Y, Li S, Gan R, Zhou T, Xu D, Li H . Impacts of gut bacteria on human health and diseases. Int J Mol Sci. 2015; 16(4):7493-519. PMC: 4425030. DOI: 10.3390/ijms16047493. View

Wu Z, Tian E, Chen Y, Dong Z, Peng Q . Gut microbiota and its roles in the pathogenesis and therapy of endocrine system diseases. Microbiol Res. 2022; 268:127291. DOI: 10.1016/j.micres.2022.127291. View

Fulbright L, Ellermann M, Arthur J . The microbiome and the hallmarks of cancer. PLoS Pathog. 2017; 13(9):e1006480. PMC: 5608396. DOI: 10.1371/journal.ppat.1006480. View

Knight R, Callewaert C, Marotz C, Hyde E, Debelius J, McDonald D . The Microbiome and Human Biology. Annu Rev Genomics Hum Genet. 2017; 18:65-86. DOI: 10.1146/annurev-genom-083115-022438. View

Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C . The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-6. PMC: 4636487. DOI: 10.1038/nm.3967. View

Purcell R, Visnovska M, Biggs P, Schmeier S, Frizelle F . Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Sci Rep. 2017; 7(1):11590. PMC: 5599497. DOI: 10.1038/s41598-017-11237-6. View

Schwabe R, Jobin C . The microbiome and cancer. Nat Rev Cancer. 2013; 13(11):800-12. PMC: 3986062. DOI: 10.1038/nrc3610. View

Liu Y, Baba Y, Ishimoto T, Gu X, Zhang J, Nomoto D . Gut microbiome in gastrointestinal cancer: a friend or foe?. Int J Biol Sci. 2022; 18(10):4101-4117. PMC: 9274484. DOI: 10.7150/ijbs.69331. View

Wang W, Zhou Y, He J, Feng Z, Zhang L, Lai X . Characterizing the composition of intestinal microflora by gene sequencing. World J Gastroenterol. 2020; 26(6):614-626. PMC: 7029349. DOI: 10.3748/wjg.v26.i6.614. View

10.

Durazzi F, Sala C, Castellani G, Manfreda G, Remondini D, De Cesare A . Comparison between 16S rRNA and shotgun sequencing data for the taxonomic characterization of the gut microbiota. Sci Rep. 2021; 11(1):3030. PMC: 7862389. DOI: 10.1038/s41598-021-82726-y. View

11.

Kim H, Kim S, Jung S . Instruction of microbiome taxonomic profiling based on 16S rRNA sequencing. J Microbiol. 2020; 58(3):193-205. DOI: 10.1007/s12275-020-9556-y. View

12.

Laudadio I, Fulci V, Palone F, Stronati L, Cucchiara S, Carissimi C . Quantitative Assessment of Shotgun Metagenomics and 16S rDNA Amplicon Sequencing in the Study of Human Gut Microbiome. OMICS. 2018; 22(4):248-254. DOI: 10.1089/omi.2018.0013. View

13.

Zhao M, Chen X, Yang Z, Yang X, Peng Q . Bacteria and tumor: Understanding the roles of bacteria in tumor genesis and immunology. Microbiol Res. 2022; 261:127082. DOI: 10.1016/j.micres.2022.127082. View

14.

Kuhn K, Stappenbeck T . Peripheral education of the immune system by the colonic microbiota. Semin Immunol. 2013; 25(5):364-9. PMC: 3864652. DOI: 10.1016/j.smim.2013.10.002. View

15.

Hanahan D . Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022; 12(1):31-46. DOI: 10.1158/2159-8290.CD-21-1059. View

16.

Shetab Boushehri M, Lamprecht A . TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings. Mol Pharm. 2018; 15(11):4777-4800. DOI: 10.1021/acs.molpharmaceut.8b00691. View

17.

Belkaid Y, Hand T . Role of the microbiota in immunity and inflammation. Cell. 2014; 157(1):121-41. PMC: 4056765. DOI: 10.1016/j.cell.2014.03.011. View

18.

Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski T . The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018; 359(6382):1366-1370. DOI: 10.1126/science.aar6918. View

19.

Park J, Kim M, Kang S, Jannasch A, Cooper B, Patterson J . Short-chain fatty acids induce both effector and regulatory T cells by suppression of histone deacetylases and regulation of the mTOR-S6K pathway. Mucosal Immunol. 2014; 8(1):80-93. PMC: 4263689. DOI: 10.1038/mi.2014.44. View

20.

Lu Y, Yuan X, Wang M, He Z, Li H, Wang J . Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J Hematol Oncol. 2022; 15(1):47. PMC: 9052532. DOI: 10.1186/s13045-022-01273-9. View